Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancers

被引：4

作者：

Awada, A ^{[1
]}

Lalami, Y ^{[1
]}

机构：

[1] Inst Jules Bordet, Med Oncol Clin, B-1000 Brussels, Belgium

来源：

CURRENT OPINION IN ONCOLOGY | 2005年 / 17卷 / 03期

关键词：

D O I：

10.1097/01.cco.0000156984.81195.46

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：209 / 211

页数：3

共 13 条

[1] Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer [J].

Ataman, ÖU ;

Bentzen, SM ;

Wilson, GD ;

Daley, FM ;

Richman, PI ;

Saunders, MI ;

Dische, S .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (18) :2734-2741

[2]

BONNER JA, 2004, P ASCO

[3] Molecular introduction to head and neck cancer (HNSCC) carcinogenesis [J].

Chin, D ;

Boyle, GM ;

Theile, DR ;

Parsons, PG ;

Coman, WB .

BRITISH JOURNAL OF PLASTIC SURGERY, 2004, 57 (07) :595-602

[4] The expanding role of systemic therapy in head and neck cancer [J].

Cohen, EEW ;

Lingen, MW ;

Vokes, EE .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1743-1752

[5]

Le QT, 2003, CLIN CANCER RES, V9, P4287

[6]

LEFEBVRE JL, 2004, P ASCO

[7] Is there still a role for neoadjuvant chemotherapy in head and neck cancer? [J].

Licitra, L ;

Vermorken, JB .

ANNALS OF ONCOLOGY, 2004, 15 (01) :7-11

[8] Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck [J].

Soulieres, D ;

Senzer, NN ;

Vokes, EE ;

Hidalgo, M ;

Agarwala, SS ;

Siu, LL .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :77-85

[9] Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation [J].

Thomas, SM ;

Grandis, JR .

CANCER TREATMENT REVIEWS, 2004, 30 (03) :255-268

[10]

TRIGO J, 2004, P ASCO

← 1 2 →